Depotwettbewerb USA 31 - 34 KW

So Freunde, traden wird auf Eis gelegt, 3 Wochen soll es gehen.
Ich hab mir nur 4 Shares reingelegt, bin aber von allen vieren restlos überzeugt.
Der Chart passt, alle vier haben diese Woche Quartalszahlen über den Erwartungen gemeldet.

Gruss E.

http://mgroen.bei.t-online.de/Er%f6ffnung%2031%20-34%20KW.jpg"


Pavian, Du bist der Einzige, der zu Shares ins Detail geht, so wie ich es auch mag.
Deshalb zeig ich für Dich nochmal exklusiv die Zahlen von meinem Top-Tipp CARA, den ich seit 4 Dollar anpreise wie Sauerbier.
CARA hat 10 Zulassungen von der FDA in den letzten 2 Jahren bekommen, das hat kaum ein Pharmagigant geschafft.
NHLC und CARA, klasse Shares derzeit. NHLC mal im 5 Jahreschart angesehen?
Übrigens ist FLML bereits bei 22 Dollar, warum haben wir die rausgeworfen?
Ich habe mich damit abgefunden, dass wir ein kleiner Kreis sind, aber mache mich etwas unsichtbarer.

Meine Adresse lautet MGroen@t-online.de, diesen Weg stelle ich zur Verfügung, falls jemand was Nettes hat.
Die einzige Adresse, die ich hab, ist die von estrich.
Dem schick ich wieder gerne Weihnachtsgrüsse, weil er sympathisch ist und hier konstruktiv das Forum bereichert.

Gruss E.

Caraco Pharmaceutical Reports Record Q2 2003, Midyear Results  
       FRIDAY, JULY 25, 2003 9:56 AM
- PR Newswire

DETROIT, Jul 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) posted record results for the second quarter and first half of 2003, Narendra N. Borkar, Chief Executive Officer, reported today.

Q2 Results

Net income for the second quarter was $4,326,158, or $0.17 per diluted share, a sharp turnaround from a net loss of $1,909,840, $0.08 per diluted share, for the second quarter of 2002. Both gross and operating income also improved appreciably. Gross profit rose 144% to $7,462,473, from $3,061,528 a year ago. The operating profit was $4,695,649, up 406% from Q2-2002 operating loss of $1,534,406.

Revenues for the quarter rose a robust 111% to $11,889,937, from $5,627,449 a year ago. Q2 revenues rose 36% over Q1 revenues of $8,721,600.

Six-month results

Midyear results were exceptional, as well. Net income jumped to $6,530,906, or $0.26 per diluted share, from a year earlier net loss of $2,429,533, or $0.11 per diluted share. The gross profit improved to $11,958,124 from $4,515,940 for the first six months of 2002. Operating profit improved similarly, rising to $7,341,585, from an operating loss of $1,685,971, a year ago.

Revenues for the first half jumped 131% to $20,611,537, from year-earlier revenues of $8,929,408.

Mr. Borkar said, "We are proud of our results for the second quarter and first half of 2003. Our gross margin and net income were substantially improved, reflecting higher sales, manufacturing efficiencies and larger production batches. The favorable results also underscore the success of our efforts in new product introduction and vertical-integration and the purchase of raw materials and active substances at highly competitive prices. Much of the credit for these accomplishments goes to our affiliate, Sun Pharmaceutical Industries, which is an FDA-approved supplier of certain active substances.

"In addition to the substantial growth in sales and strong profitability, we introduced one new drug, clozapine, a generic form of Clozaril, during the quarter. This raises our formulary to 16 drugs.

"Looking forward, we are optimistic about the third quarter and second half of 2003. We expect continued growth in sales and strong gross-profit margins in the third and fourth quarters. As reported, our sales for the year are expected to increase more than 50% to $35 million. We, likewise, expect profitability in quarters in which we do not recognize technology transfer expenses for new drugs under our R&D agreement with Sun Pharma.

"We plan to introduce one new drug, digoxin, a generic form of Lanoxin, in the third quarter. By yearend, we expect to receive two or three drug approvals from the FDA," he said. He noted that the Company has 15 drugs in various stages of development.

Caraco has received FDA approval for 10 generic drugs over the past two years. These are: digoxin, a generic form of Glaxo Wellcome's Lanoxin; clozapine, a generic form of Novartis' Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche's Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo's Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb's Glucophage; oxaprozin, a generic form of G.D. Searle's Daypro; carbamazepine (chewable), a generic form of Novartis' Tegretol; clonazepam, a generic form of Roche's Klonopin; flurbiprofen, a generic form of Pharmacia's Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute's Ultram.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation's largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies. Sun Pharmaceutical Industries Ltd. is India's fifth largest pharmaceutical company and owns about one-half of Caraco's outstanding shares of common stock.